Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | CTSS | P25774 | 1/20 | 0.48 |
| ▸ | CTSK | P43235 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | ITGB3 | P05106 | 9/20 | 0.45 |
| ▸ | ITGA2B | P08514 | 9/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9103275 | 1.00 | TSHR (0.52) | TSHRCTSSCTSKKMT2AITGB3 | |
| SCHEMBL9102670 | 0.88 | CTSK (0.51) | TSHRCTSSCTSKITGB3ITGA2B | |
| SCHEMBL9102661 | 0.88 | CTSK (0.51) | TSHRCTSSCTSKITGB3ITGA2B | |
| SCHEMBL6163781 | 0.87 | TSHR (0.48) | TSHRCTSSCTSKKMT2AITGB3 | |
| SCHEMBL6163776 | 0.87 | TSHR (0.48) | TSHRCTSSCTSKKMT2AITGB3 | |
| SCHEMBL27469415 | 0.87 | CTSK (0.52) | TSHRCTSSCTSKITGB3ITGA2B | |
| SCHEMBL9103039 | 0.87 | CTSK (0.52) | TSHRCTSSCTSKITGB3ITGA2B | |
| SCHEMBL9103036 | 0.87 | CTSK (0.52) | TSHRCTSSCTSKITGB3ITGA2B | |
| SCHEMBL14736900 | 0.82 | CTSK (0.50) | TSHRCTSSCTSKITGB3ITGA2B | |
| SCHEMBL14144416 | 0.81 | HRH2 (0.47) | TSHRCTSKKMT2AMAPK1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130143858-A1 | COMPOUNDS AND THEIR USE AS IKACH BLOCKERS | ASTRAZENECA AB (SE) | 2013-06-06 | — | — | US | disclosed |
| US-8361998-B2 | Compounds and their use as IKACh blockers | ASTRAZENECA AB | 2013-01-29 | — | — | US | disclosed |
| WO-2012074469-A1 | NEW IKACH BLOCKERS | ASTRAZENECA AB (SE) | 2012-06-07 | — | — | WO | disclosed |
| US-20120142659-A1 | COMPOUNDS AND THEIR USE AS IKACH BLOCKERS | ASTRAZENECA AB (SE) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130143858-A1 | COMPOUNDS AND THEIR USE AS IKACH BLOCKERS | KCNH2, KCNJ2, KCNH3 | TSHR 304/4885CTSS 4715/4885CTSK 4102/4885 |
| US-20120142659-A1 | COMPOUNDS AND THEIR USE AS IKACH BLOCKERS | KCNH2, KCNJ2, KCNH3 | TSHR 304/4885CTSS 4715/4885CTSK 4102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.